CMS advises SYNLAB International on the sale of SYNLAB Lietuva to Affidea Lietuva

Stuttgart, 03.09.2024 – SYNLAB International GmbH, a leading provider of medical diagnostics in Europe, has sold 100 percent of its shares in its Lithuanian subsidiary SYNLAB Lietuva UAB to Affidea Lietuva UAB. The Affidea Group is, according to its own information, the largest European provider of advanced diagnostic imaging, out-of-hospital treatment and cancer screening. With this transaction, SYNLAB intends to optimize its investment portfolio and focus more strongly on its core markets. The parties involved have agreed not to disclose further details.

A CMS team headed by lead partner Dr Christoph Lächler provided comprehensive legal advice to SYNLAB International on the entire transaction. In particular, in addition to the purchase agreement documentation, an agreement on transitional services to be provided by the SYNLAB Group after completion of the transaction was also concluded. With regard to points of contact with Lithuanian law, the CMS team was supported by Deimantė Pagirienė of the World Law Group law firm COBALT Lithuania. Dr Fabian Walla, Group General Counsel, and Dr Peter Macheiner, Head of Legal M&A and Procurement, at SYNLAB in Munich, acted as in-house counsel. SYNLAB is a long-standing client of CMS and regularly relies on the expertise of the Corporate/M&A team led by Dr Christoph Lächler, most recently on the sale of its veterinary diagnostics division, SYNLAB VET, to a subsidiary of the US Mars Group.

Press Contact
presse@cms-hs.com